Evonik Industries AG (ETR:EVK)
Market Cap | 6.78B |
Revenue (ttm) | 14.71B |
Net Income (ttm) | 424.00M |
Shares Out | 466.00M |
EPS (ttm) | 0.92 |
PE Ratio | 15.90 |
Forward PE | 12.01 |
Dividend | 1.17 (8.04%) |
Ex-Dividend Date | May 29, 2025 |
Volume | 425,989 |
Average Volume | 1,364,190 |
Open | 14.55 |
Previous Close | 14.55 |
Day's Range | 14.54 - 14.73 |
52-Week Range | 14.49 - 22.39 |
Beta | 0.89 |
RSI | 28.76 |
Earnings Date | Nov 4, 2025 |
About Evonik Industries AG
Evonik Industries AG produces and sells specialty chemicals in the Asia-Pacific, Europe, the Middle East, Africa, Central and South America, and North America. It operates through Specialty Additives, Nutrition & Care, Smart Materials, and Technology & Infrastructure segments. The Specialty Additives segment offers additives for polyurethane foams; additives, matting agents, fumed silicas, and specialty resins for paints, coatings, and printing inks; isophorone and epoxy curing agents for coatings, adhesives, and composites; and pour-point depr... [Read more]
Financial Performance
Financial StatementsNews

Evonik: Revised Outlook Necessitates A Q3 2025 Update
Evonik Industries remains a fundamentally strong specialty chemicals company, now trading at attractive valuations despite recent earnings downgrades and market underperformance. EVKIY faces near-term...

EQS-DD: Evonik Industries AG: Dr. Claudine Mollenkopf, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 30.09.2025 / 11:39 CET/CEST The issuer is solely responsi...
Evonik Sees Persistently Weak Demand Until Year-end; Adjusts FY25 Outlook
(RTTNews) - Evonik Industries AG has adjusted the outlook for fiscal 2025. For 2025, Evonik had previously expected adjusted EBITDA to be between 2.0 billion and 2.3 billion euros, with the company mo...

Evonik Industries: 2025 Outlook Shift & Q3 Financials Revealed
Evonik Industries AG revises its 2025 financial outlook, reflecting market challenges and shifting demand. Jetzt den vollständigen Artikel lesen

EQS-Adhoc: Evonik Industries AG: Adjustment of the outlook for the fiscal year 2025; financial figures for the third quarter of 2025
EQS-Ad-hoc: Evonik Industries AG / Key word(s): Change in Forecast/Preliminary Results Evonik Industries AG: Adjustment of the outlook for the fiscal year 2025; financial figures for the third quarter...
Look Beyond The Volatility In Evonik Industries

EQS-DD: Evonik Industries AG: Dr. Claudine Mollenkopf, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.08.2025 / 10:16 CET/CEST The issuer is solely responsi...

EQS-DD: Evonik Industries AG: Thomas Wessel, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 05.08.2025 / 10:09 CET/CEST The issuer is solely responsi...

EQS-PVR: Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evonik Industries AG Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide ...
Evonik Industries reports Q2 results
Evonik Industries AG (EVKIF) Q2 2025 Earnings Call Transcript
Evonik Industries AG 2025 Q2 - Results - Earnings Call Presentation

EQS-PVR: Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution
EQS Voting Rights Announcement: Evonik Industries AG Evonik Industries AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide ...

EQS-AFR: Evonik Industries AG: Preliminary announcement of the publication of financial reports according to Articles 114, 115, 117 of the WpHG [the German Securities Act]
EQS Preliminary announcement financial reports: Evonik Industries AG / Preliminary announcement on the disclosure of financial statements Evonik Industries AG: Preliminary announcement of the publicat...

EQS-DD: Evonik Industries AG: Christian Kullmann, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 04.06.2025 / 11:18 CET/CEST The issuer is solely responsi...

EQS-DD: Evonik Industries AG: Dr. Claudine Mollenkopf, buy
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them 03.06.2025 / 10:46 CET/CEST The issuer is solely responsi...
Evonik Industries AG (EVKIF) Q1 2025 Earnings Call Transcript
Evonik Industries AG (OTCPK:EVKIF) Q1 2025 Results Conference Call May 12, 2025 5:00 AM ETCompany ParticipantsChristian Kullmann - Chairman of the Executive...
Evonik Industries reports Q1 results
Evonik: Decent Rate Of Return, Upside Confirmed
Evonik Industries AG (EVKIF) Q4 2024 Earnings Call Transcript
Evonik Industries reports Q4 results; initiates Q1 and FY25 outlook
Silexion Therapeutics collaborates with Evonik on advanced siRNA Formulation Development
Cayman Islands, December 17, 2024 – Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotech developing RNA interference (RNAi) therapies for KRAS-driven can...

EQS-News: Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery
EQS-News: leon-nanodrugs GmbH / Key word(s): Study results Feasibility Study with Evonik Confirms LEON’s FR-JET Technology’s Performance in Advanced Nanoparticle Manufacturing for Drug Delivery 05.12....